Breast Cancer Clinical Staging

Tumor Classification

• The American Joint Committee on Cancer (AJCC) classifies tumors larger than 2 cm but not larger than 5 cm as T2 1
• A tumor measuring exactly 4 cm is firmly placed in the T2 category, according to the AJCC criteria 1, 2

Lymph Node Classification

• The absence of axillary lymph node involvement confirmed by pathological evaluation is classified as N0, according to the AJCC 1, 3
• A thorough evaluation of the lymph nodes, ideally through sentinel lymph node biopsy, is crucial for accurate staging 4

Final Clinical Stage

• A patient with T2N0M0 is considered to have clinical stage IIA, according to the National Comprehensive Cancer Network (NCCN) guidelines 1, 3

Additional Prognostic Factors

• A positive HER2 status is a crucial prognostic and predictive factor that modifies the therapeutic approach, and patients with HER2-positive tumors are candidates for targeted therapy with trastuzumab 5, 6
• HER2-positive tumors larger than 1 cm with negative lymph nodes are appropriate candidates for systemic adjuvant chemotherapy plus anti-HER2 therapy 2, 3

Treatment Implications

• For a T2N0M0 HER2-positive tumor, systemic adjuvant treatment is recommended, according to the NCCN guidelines 1, 3
• Adjuvant chemotherapy is indicated (category 1) for tumors larger than 1 cm 2, 3
• Anti-HER2 therapy with trastuzumab should be considered for HER2-positive tumors 5, 6
• If the tumor is also hormone receptor-positive (ER/PR+), endocrine therapy should be added after completing chemotherapy 3, 6

Additional Recommended Evaluation

• Before initiating systemic treatment, consider complete staging, including CT scans of the chest, abdomen, and pelvis with contrast to rule out metastatic disease, as recommended by the NCCN guidelines 1, 7
• Confirm the status of hormone receptors (ER and PR) if not already determined 1, 8
• Baseline cardiac evaluation, including left ventricular ejection fraction (LVEF) assessment, is required before initiating trastuzumab therapy 6